Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation
08 sept. 2020 08h00 HE
|
Resverlogix Corp
CALGARY, Alberta, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces its participation at the GCFF Virtual Conference 2020 - Investing in...
Resverlogix Provides Update Regarding Extension of its Filing Calendar
28 août 2020 18h30 HE
|
Resverlogix Corp
CALGARY, Alberta, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that, further to its July 28, 2020 press release, it continues to rely on...
Resverlogix Announces Private Placement
14 août 2020 18h19 HE
|
Resverlogix Corp
CALGARY, Alberta, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today it has closed a private placement of 3,573,333 equity units at a...
Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
04 août 2020 08h00 HE
|
Resverlogix Corp
CALGARY, Alberta, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today the recent publication of an article titled: “Epigenetic...
Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption
28 juil. 2020 18h00 HE
|
Resverlogix Corp
CALGARY, Alberta, July 28, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it intends to rely on blanket exemptions issued by provincial...
Resverlogix Secures One-Year Extension of Maturity Date of Debenture
22 juil. 2020 07h00 HE
|
Resverlogix Corp
CALGARY, Alberta, July 22, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has closed a one-year extension of the maturity date of its...
Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
22 juin 2020 07h00 HE
|
Resverlogix Corp
CALGARY, Alberta, June 22, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that the U.S. Food & Drug Administration (FDA) has accepted its BETonMACE2...
Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress
09 juin 2020 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, June 09, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce key data from its BETonMACE clinical trial in pre-specified stage 3 chronic...
Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020
05 juin 2020 18h54 HE
|
Resverlogix Corp
CALGARY, Alberta, June 05, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the Company will host a Corporate Update Conference Call and...
Resverlogix Plans COVID-19 Clinical Trial Program Launch
01 juin 2020 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, June 01, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that it is moving forward with a plan to further evaluate...